The Vanderbilt-Ingram Cancer Center is at the forefront of lung cancer and mesothelioma treatment, providing screenings, second opinions and individualized treatment for a patient’s cancer.
Specialists at the Vanderbilt-Ingram Cancer Center have experience diagnosing the disease, as well as providing second opinions, with a variety of tests like CT scans, MRIs and endoscopic ultrasounds. The center provides a variety of treatment options depending on the patient’s individual case, including advanced robotic surgery, minimally invasive surgery, immunotherapy, radiation and chemotherapy. Radiation is used as a treatment or as a palliative therapy to reduce symptoms and manage pain. The center offers targeted therapy, biologic therapy and clinical trials to patients as alternative treatment options, as well. They assess the cancer on an individual basis, using genetic testing to find the best treatment options.
Patient navigators are also available to patients to relieve them of the stress of scheduling appointments and collecting medical and financial records. Patients may access survivorship and support services as part of their care at the Vanderbilt-Ingram Cancer Center.
Specializations:
- Chemotherapy
- Radiation therapy
- Surgery
- Targeted therapy
Accreditations:
- CEO Cancer Gold Standard
- National Cancer Institute (NCI) Comprehensive Care Center
- National Cancer Institute (NCI) National Clinical Trials Network accreditation
- National Comprehensive Cancer Network (NCCN) accreditation
Mesothelioma Clinical Trials at Vanderbilt-Ingram Cancer Center
The following clinical trials are in progress or actively recruiting participants at Vanderbilt-Ingram Cancer Center:
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Conditions: Mesothelioma, Lung Neoplasms, Neoplasms
Last Updated: March 2, 2020
Status: Active, not recruiting
Collecting Tumor Samples From Patients With Gynecological Tumors
Conditions: Carcinoma, Carcinoma, Squamous Cell, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Neoplasms, Germ Cell and Embryonal, Mesothelioma, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Rhabdomyosarcoma, Germinoma, Leiomyosarcoma, Vulvar Neoplasms, Vaginal Neoplasms, Cystadenocarcinoma, Trophoblastic Neoplasms, Gestational Trophoblastic Disease, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Cystadenocarcinoma, Serous, Carcinoma, Adenosquamous, Brenner Tumor, Sarcoma, Endometrial Stromal, Rhabdomyosarcoma, Embryonal, Neoplasms
Last Updated: October 26, 2016
Status: Completed
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Conditions: Carcinoma, Merkel Cell, Carcinoma, Lung Neoplasms, Melanoma, Small Cell Lung Carcinoma, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Mesothelioma, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck, Microsatellite Instability
Last Updated: October 22, 2019
Status: Recruiting
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Conditions: Carcinoma, Renal Cell, Mesothelioma
Last Updated: February 26, 2020
Status: Recruiting
Related pages
Get Help Contacting Vanderbilt-Ingram Cancer Center
Free
Mesothelioma Treatment Guide
Please fill in the form to request our FREE Mesothelioma Treatment Guide.
It will be sent to you within 24 hours.
